|
Indian Pediatr 2017;54: 542-543 |
|
The Confrontation of Fungal Sepsis in
Neonates
|
Rumpa Saha
Department of Microbiology, University College of
Medical Sciences, Dilshad Garden, Delhi 110095, India.
Email:
[email protected]
|
P resent day neonatal care has enhanced survival of
extremely low birth weight babies but augmented the requirement for
multiple invasive modus operandi intensifying the curse of
healthcare-associated infections. Escalation in incidence of fungal
sepsis is one of the inevitable effects of such advancement. A favorable
outcome in neonates with fungal septicemia depends on timely clinical
suspicion and institution of appropriate antifungal therapy,
identification of end organ damage, and close follow-up. It thus becomes
imperative for neonatologists to recognize babies at highest risk for
fungemia. The risk factors for acquiring fungal sepsis have been
extensively studied. Mortality associated is distressingly high, and it
is imperative to be acquainted with risk factors for poor outcome.
Candida has emerged to be one of the most common
causes of neonatal fungemia, and accounts for up to 13% of such
infections with most of the surveillance studies reporting a rising
trend [1]. It ranks fourth in the United States and seventh in
Europe among the causes of nosocomial blood stream infection
[2,3]. Candida albicans is the third most
common cause of neonatal late onset sepsis in infants whose birth weight
is less than 1500 g, as demonstrated by a multicenter study from the
National Institute of Child Health and Human Development Neonatal
Research Network [4]. An illustration from the National Nosocomial
Infection Surveillance points out that the occurrence of these
hospital-acquired pathogens is greatest in extremely low birth weight
infants (birth weight <1000g) [5].
Until recently, C. albicans was by far the
predominant species in most countries, responsible for 60% of all cases
of candidemia. However, recently several countries around the world have
witnessed a change in the epidemiology of Candida infections,
characterized by a progressive shift from a predominance of C.
albicans to non-albicans Candida species notably C.
tropicalis, C. parapsilosis, C. krusei, C. guilliermondii
and C. glabrata. Evidence suggests a role for increasing use
of azole antifungals in this epidemiological shift. Some of these non-albicans
Candida species (e.g., C. glabrata and C. krusei)
exhibit intrinsic resistance to traditional triazole agents like
fluconazole, and may also demonstrate cross-resistance to newer
triazoles [6]. This makes it imperative to perform both speciation and
antifungal susceptibility testing of all yeasts from patients with
invasive candidiasis. Due to considerable regional inconsistency, local
epidemiological awareness is paramount in the successful management of
such Candidia infections.
A comparatively newer species, Candida auris,
is being increasingly reported from many Indian states since its first
report from Japan in 2009. From India, C. auris was first
reported from northern India. Since then, this has emerged as an
important challenge in the management of patients due to its outbreak
potential, multidrug resistance and associated high mortality. It is
underreported because it is commonly misidentified in the routine
diagnostic laboratories as C. haemulonii or C. famata by
commercial identification systems. Sequencing of the Internal
transcribed spacer (ITS) region and the D1/D2 region of the large
subunit (28S) of the ribosomal DNA or even Matrix assisted laser
desorption ionization – time of flight (MALDI-TOF) mass spectrometry can
confirm the identity of this oval yeast, which does not form
pseudohyphae/germ tube, and fails to grow in the presence of 0.01% or
0.1% cyclohexamide, but can grow at 42 0C,
and ferment maltose [7].
Even identification of C. haemulonii is difficult as it is
phenotypically very similar to C. famata and C. guilliermondii
[8].
The research paper by Basu, et al. [9]
published in this issue of Indian Pediatrics evaluates the local
epidemiology of neonatal candidemia in and around city of Varanasi in
India. As their study came across non-albicans Candida species in nearly
double the number of C. albicans candidemia, the authors have
very nicely estimated the predictors of such an outcome. Identification
and prevention of such risk factors in susceptible neonates can
significantly improve outcome of neonates with fungal sepsis. The
authors have been able to characterize phenotypically 82 out of 114
isolates of Candida to the species level. Although phenotypic or
commercially available rapid detection systems may be useful for
clinicians, they often lack reproducibility. MALDI-TOF biotyper is an
exception, which, as well as DNA sequencing correctly identifies Candida
up to the species level. Hence, molecular methods though expensive, but
reproducible and reliable, should be adopted by tertiary care hospitals
for monitoring and surveillance of important hospital-associated bugs.
Antifungal susceptibility is very essential for
effective treatment and the authors have also done susceptibility
testing of their Candida isolates by disc diffusion test. Minimum
inhibitory concentration (MIC) determination as per Clinical and
Laboratory Standards Institute (CLSI) M27-A3 guidelines may be more
reliable in such circumstances as also increasing the number of
antifungals to include newer azoles (like ravuconazole, posaconazole)
and echinocandins, as often some isolates are multidrug resistant
(resistant across two antifungal classes). For echinocandins, disk
diffusion is not recommended by CLSI. As breakpoint MICs for some newer
Candida species is still not defined by CLSI M 27-A3,
breakpoint suggested for yeast in CLSI M27-S4
can be used for such interpretations.
The knowledge of possible source of such fungimea is
imperative for future preventive strategies. As most of the surveillance
studies report a rising trend in neonatal candidemia over the years, the
authors could possibly have done a trend analysis to evaluate any such
inclination. This is equally essential for scrutinizing surveillance
programs and policy formulation.
To conclude, candidemia in the neonates is a
challenging condition not only for the clinicians but also for the
microbiologists. Risk factor identification along with speciation and
drug susceptibility testing is crucial for timely management of such
neonates.
Funding: None; Competing interests: None
stated.
References
1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald
SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely
low birth weight infants: Risk factors, mortality rates, and neuro-developmental
outcomes at 18 to22 months. Pediatrics. 2006;117:84-92.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H,
Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals:
Analysis of 24,179 cases from a prospective nationwide surveillance
study. Clin Infect Dis. 2004;39:309-17.
3. Marchetti O, Bille J, Fluckiger U, Eggimann P,
Ruef C, Garbino J, et al. Epidemiology of candidaemia in Swiss
tertiary care hospitals: Secular trends, 1991-2000. Clin Infect Dis.
2004;38:311-20.
4. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo
WA, Ehrenkranz R, et al. Late-onset sepsis in very low birth
weight neonates: the experience of the NICHD Neonatal Research Network.
Pediatrics 2002;110:285-91.
5. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan
T. Changing incidence of Candida bloodstream infections among NICU
patients in the United States: 1995-2004. Pediatrics. 2006;117:1680-7.
6. Magill SS, Shields C, Sears CL, Choti M, Merz WG.
Triazole cross-resistance among Candida spp.: Case report,
occurrence among bloodstream isolates, and implications for antifungal
therapy. J Clin Microbiol. 2006;44:529-35.
7. Rudramurthy SM, Chakrabarti A, Paul RA, Sood P,
Kaur H, Capoor MR, et al. Candida auris candidaemia in
Indian ICUs: Analysis of risk factors. J Antimicrob Chemother.
2017;72:1794-1801.
8. Lehmann PF, Wu LC, Pruitt WR, Meyer SA, Ahearn DG.
Unrelatedness of groups of yeasts within the Candida haemulonii
complex. J Clin Microbiol. 1993;31:1683-7.
9. Basu S, Kumar R, Tilak R, Kumar A. Candida blood
stream infection in neonates: Experience from a tertiary care teaching
hospital of central India. Indian Pediatr. 2017;54: 556-9.
10. Clinical and Laboratory Standards Institute.
Reference Method for Broth Dilution Antifungal Susceptibility Testing of
Yeasts—Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA,
2008.
11. Clinical and Laboratory Standards Institute.
Reference Method for Broth Dilution Antifungal Susceptibility Testing of
Yeasts: Fourth Informational Supplement M27-S4. CLSI, Wayne, PA,
USA, 2012.
|
|
|
|